According to Google’s Health boss David Feinberg... over one billion people a day search Google for health concerns.
But, what if, instead... they could "consult" a phone app with the power of hundreds of doctors?
After five years in beta, we think that they are about to disrupt the $11.8 trillion healthcare industry.
It will be available to 300million smartphone users in USA
And that’s just for starters. Eventually, it could target the world’s 3.8 billion users.
TECH DISRUPTIONS CAN LIFT ALL STOCKS IN THE SECTOR: THE AI HEALTHCARE MARKET WILL SOON GROW 18X TO $120 BILLION
The AI healthcare market is growing at an astonishing rate.
It's growing at a compound annual growth rate of 41% a year, according to GrandView Research.
Some predict it will go from $6.7 billion a year to $120 billion a year in revenue by 2028 That’s 18X growth.
The smart money is moving into this sector now, chasing these potential returns.
So, how does Treatment’s Carabreakthrough AI app work?
Cara was trained by hundreds of doctors to think like a doctor to be your personalized symptom-checker, provide intelligent follow-up, and manage healthcare for your entire family.
Not only was it trained by doctors, but it’s also licensed to train doctors at the University of Minnesota’s medical school.
HOW AI IS CHANGING HEALTHCARE: CHEAPER AND INCORPORATES THE SKILL AND EXPERIENCE OF HUNDREDS OF DOCTORS
Instead of turning to Google…
Tens of millions of people are now turning to the next generation of health apps…
And those apps have been statistically proven at times to be better than actual doctors at performing correct diagnoses and providing the right medical guidance and prescriptions.
Cardiologists are now competing with IBM’s Watson Health, which has a track record of diagnosing heart disease better.
The entire healthcare sector is undergoing digitization, whether it's something as basic as patient records, as convenient as wearables or as complex as AI diagnosis. It’s redefining healthcare monumentally.
According to TechCrunch’ Kai-Fu Lee, diagnostic AI will “surpass all but the best doctors in the next 20 years”.
And studies have already demonstrated that AI trained on big enough data can outperform doctors in various elements of diagnosis--from brain tumors and skin cancer, to eye disease, breast cancer and lung cancer.
And the COVID-19 pandemic is accelerating the disruption . And even then, an April 2020 study found that an AI system managed to detect 17 out of 25 positive COVID-19 cases based on normal CT images, while professionals had failed to detect any.
This could be the biggest disruption the $11.9-trillion global healthcare industry has ever seen. And it’s just getting started.
DOCTORS IN YOUR POCKET: CARA’S BREAKTHROUGH SELF DIAGNOSIS TECHNOLOGY
Like Amazon disrupted retail...
Like Netflix disrupted everything from cable TV to Hollywood …
How? By empowering consumers to take control of their healthcare in an increasingly dysfunctional system that is impossible to navigate and wildly unaffordable.
For the past 5 years, Cara's tech team has been harnessing the power of AI...
To develop a more accurate smartphone AI engine.
The biggest opportunity in an AI healthcare sector that hit $120 billion in 2020 and some predict will hit an unbelievable $4 billion by 2025 is going "direct to consumer".
Currently, people try to self-diagnose online… But soon that will change.
Treatment’s Mobile application with Cara Digital Health Assistant provides users with tailored assessments and recommendations from personal medical history, wearable data and individual tracking data.
It also provides intelligent, AI-powered follow-ups--just like a doctor. It integrates intelligent tracking and monitoring into a single app to support health and illness prevention.
And it seeks to become the most accurate health data on the market -- this AI has been trained by a global team of doctors, engineers and mathematicians to continually learn--until all ~10,000 diseases known to man is part of Cara’s intelligence portfolio.
It's been so successful that it's now being licensed by universities to train doctors.
And now, by the end of October, this same technology -- the Cara Health App -- will launch in the public ...
Giving you the power of a huge number of doctors in your smartphone.
A first or second opinion is only a tap away.
The market is limitless…
A POTENTIAL AUDIENCE OF 3.8 BILLION SMARTPHONE USERS
The direct-to-consumer phone app model is one of the most profitable in history...
And first-movers in new categories become tomorrow’s big stock winners.
WebMD isn’t a publicly traded company, and it’s valued at $2.8 billion--without any intelligent AI or healthcare management aspect at all.
Babylon Health is valued at $4.2 billion now and is gearing up to go public.
But Cara is a breakthrough.
It's the next gen app and could become worth more than the others in the industry.
Considering the estimated one billion Google searches a day for health concerns... Cara only needs a 1% market penetration... To gain 10 million new users.
10 million users could turn this small company into a multi-billion-dollar household name.
It’s already clear that the multi-trillion-dollar healthcare industry is being thoroughly disrupted by AI …
AI in the healthcare industry will grow by multiples more … from $6.7 billion to over $194 billion by 2030...
With a direct-to-consumer model …
That links the consumer up with wellness, telemedicine, pharma and health products for multiple revenue generators, plus collects a goldmine of data that could ping major industry radar …
The Treatment Mobile, Cara app could become as big as any of its 3 competitors... even bigger.
If it does, it could turn this small $371-million market cap company into a multi-billion-dollar household name.
The time to get in is now… before it launches. And we’re just weeks away from that.
Big Pharma is also working to tackle the new reality in healthcare:
Pfizer Inc (NYSE:PFE) headquartered in New York City, is an American multinational pharmaceutical corporation. They're the world's largest research-based pharmaceutical company and market leader of prescription drugs globally. Pfizer has had a long history of innovation that includes breakthrough treatments for many diseases such as cancer and heart disease. The company also pioneered the development of vaccines against infectious diseases such as influenza and pneumonia. In more recent years they've been working to find new ways to address unmet needs by bringing forth novel medicines with different mechanisms or new uses for existing medicines to treat major health conditions including Alzheimer's disease, Parkinson's disease, schizophrenia and depression.
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They include the Zoloft brand from Pfizer Inc. While Pfizer dominated headlines the past year due to its COVID-19 vaccine, the company’s contributions to mental health cannot be ignored. Zoloft is one of the world’s most recognizable antidepressants. The drug works by preventing the movement of serotonin back into nerve endings, essentially making the chemical more available for the body to use. This is important because low levels of serotonin have been linked to depression, anxiety, and even obsessive-compulsive behavior.
Pfizer’s Zoloft set itself apart of the many other brands of SSRIs thanks to its tolerability. In many studies, Zoloft has proven itself a drug with minimal negative side-effects, making it one of the first medicines doctors try for many people suffering with depression.
Pfizer’s share price saw a lot of volatility over the past year, but the company remains one of the top drug producers on the planet, and as such, especially with its attractive dividends, Pfizer will likely be a safe investment for years to come.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company, headquartered in Petah Tikva, Israel. It manufactures and markets generic drugs to fight medical conditions that are not well-served by the proprietary medicines of large drug companies. TEVA has a product portfolio of more than 1,000 molecules across its therapeutic areas including neurology, cardiovascular disease, anti-infectives and women's health care among others. The company also produces active pharmaceutical ingredients used in the manufacture of prescription drugs for other manufacturers as well as over-the-counter products such as vitamins and dietary supplements.
Teva Pharmaceutical Industries is another major pharmaceutical company that, largely due to its series of aggressive expansion and acquisitions has played a major role in helping patients get the treatment they need. In fact, its focus on generic, non-brand-name, medications have made treatment of depression more affordable than ever. Some of the medications it distributes include escitalopram, a generic version of the widely popular Lexapro, and venlafaxine, which some may recognize as Effexor.
Teva, like some of its Big Pharma peers, has also seen a particularly turbulent year. Though its stock price is sitting just shy of its price one year ago, the company’s multi-pronged approach to the industry positions it well for further growth.
Johnson & Johnson (NYSE:JNJ) is the world's largest healthcare company. It has a wide variety of products, including pharmaceuticals and consumer goods. The company focuses on research, development, manufacturing and marketing to provide quality care for people all over the world.
Johnson & Johnson is committed to improving lives by bringing innovative ideas to market in healthcare, nutrition, and beauty. This includes medicines that help people battle cancer or mental illness; nutritional supplements that promote healthy living; baby care products that protect against diaper rash; cleaning supplies that keep homes fresh-smelling clean; cosmetics that enhance natural beauty; household cleaners with effective germ-killing ingredients
Johnson & Johnson is another company that has received significant attention due to its COVID-19 vaccine, has also received widespread praise in the medical community. Not only is the medication the first of its kind, it has also had overwhelmingly positive benefits to the patients utilizing the drug. The drug showed improvement in depression symptoms for periods of time as long as four weeks.
Though patients are not able to use the medicine without direct supervision from a healthcare provider due to the side effects, the procedure has proven to be safe and sustainable in the long run. This is huge news for individuals suffering from depression, and this new treatment could be an absolute game-changer over time.
Allergan plc (NYSE:AGN) is a multinational pharmaceutical company that specializes in the development and selling of new, innovative treatments for eye diseases. Founded back in 1947 by two doctors, Allergan plc has grown to be one of the most trusted names in medicine today with over 100 different products on the market.
Allergan plc's success can be attributed to their team of scientists who are dedicated to making groundbreaking discoveries. They also maintain an open-door policy for all physicians so they can learn about their newest innovations firsthand.
Allergan plc, primarily known for its Botox branded injection, is working to create a ketamine-like injectable depression treatment called Rapastinel. The company acquired the brand when it bought out Naurex for $560 million. While the drug was undergoing testing, it has hit a few snags along the way. Namely, in its most recent round of testing, it failed to differentiate from a placebo on the primary and key secondary endpoints.
Though Rapastinel has since been discontinued, Allergan is already working on a new treatment for depression and bipolar disorder in its drug, VRAYLAR, and it’s already been approved by the FDA for testing.
Merck & Co. (NYSE:MRK) is a pharmaceutical company that was founded in 1891. The company has been researching, developing, manufacturing and distributing prescription drugs for over the past century. Merck & Co.'s research efforts are focused on areas such as cancer, HIV/AIDS and Alzheimer's disease. They also provide healthcare services to people living in countries where there is limited or no medical infrastructure by providing medicines, vaccines and other medical supplies to them at affordable prices through their Merck Foundation arm of the business.
Year-to-date, Merck & Co. has had a fairly turbulent year. It started the year off in January sitting at near $79 per share before dropping to $69 in early March. The company did, however recuperate some of its losses by July, before another significant drop-off in September. Since its last dip, however, the company has charged ahead and is now sitting at $80 per share. The changes highlight some of retail investors’ decisions to hop off the vaccine train and dive back into investing in some significant pharmaceutical developments.
With much of the COVID-19 hype dying down, companies with strong products and research and development teamslike Merck & Co. stand to regain some of their ground among the vaccine allstars. This bodes well for Merck & Co. in the coming months, and the $200 billion company is a good pick for investors looking into the future.
A lot can be said about how food providers are helping the health and wellness movement flourish, as well. Take, Burcon NutraScience Corporation (TSX:BU), for example. Burcon is a Canadian tech firm rethinking the plant-based diet. With a focus on high-purity, sustainable, flavorful, and affordable products, Burcon has checked every box in the consumer’s book. Founded way back in 1998, the company has been at the forefront of the movement for over two decades, and it’s only become more refined since.
According to its mission statement, Burcon “seeks to improve the health and wellness of global consumers through the discovery and development of sustainable, functional and renewable plant-based products for the global food and beverage industries.”
Else Nutrition Holdings Inc. (CSE:BABY) is another innovative plant-based lifestyle company from Canada. Else Nutrition has taken a different approach than many of its competitors, targeting a particularly young market – babies. Else was a first-mover in this space, offering a well-rounded, clean, sustainable and most importantly, plant-based, approach to baby food.
Their products aim to deliver al of the same benefits as typical baby food, but with an organic twist. In fact, 92% of their products are made from three core healthy ingredients, almonds, tapioca, and buckwheat. And the best part, is they never alter the plants’ chemistry or remove any of the micronutrients, they just alter the texture.
Maple Leaf Foods (TSX:MFI) is another veteran in the Canadian foods realm. Since 1991, Maple Leaf has been making aggressive acquisitions, supplying high-quality foods, and leading in new innovations to ensure the highest quality products for all of its consumers around Canada. And just last year, it announced its plans to dive head first into the plant-based foods industry with a $310 million facility in Shelbyville, Indiana.
More than that, however, Maple Leaf Foods is also committed to slashing its own carbon footprint. In fact, on November 7, 2019, the company announced that it was the first major carbon-neutral food company – a huge claim to fame in a world racing to go green.
The Very Good Food Company Inc. (CSE:VERY) is a Canadian company that is quickly gaining a lot of ground in the market. With the slogan, “we believe in butchering beans, not animals,” they’re looking to tap into the plant-based niche in a hurry. And it’s resonated very well with investors.
Since its IPO in June, the Very Good Food Company has seen its share price grow by over 70%, and it’s showing no signs of slowing. In just a few short months, the company has opened several new facilities, signed a string of deals, and is quickly carving out its place in Canada’s fast-growing plant-based lifestyle scene.
Modern Meat Inc (CSE:MEAT) is a Canadian company following directly in the footsteps of its American cousin, Beyond Meat. With a focus on Instagram-worthy products that could easily garner the interest of any meat-eater, the company is looking to make the plant-based lifestyle trendy. And consumers are loving it.
The company announced in early October that its stock had sold out for over 15 weeks in a row. "We are pleased to announce that our sellout streak is continuing and there is an obvious demand for our products. Despite the interest in our products we are currently constrained by our production capacity and continuing the set-up of our new facility," stated Tara Haddad, Chief Executive Officer of the Company.
By. Joao Piexe
** IMPORTANT NOTICE AND DISCLAIMER -- PLEASE READ CAREFULLY! **
PAID ADVERTISEMENT. This article is a paid advertisement. Advanced Media Solutions Ltd. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International, Inc. Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher to produce and disseminate six articles profiling the Company at a rate of seventy-five thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the company’s products, the anticipated growth of the market for AI-assisted products generally, the anticipated growth of the market for app-based products generally, the anticipated launch date for the company’s products, the anticipated growth of the market for health care app-based products generally, the anticipated launch date for the company’s products, and the anticipated growth and expansion of the medical library to which the company’s products have access. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the AI technology used in the company’s products, the company’s ability to effectively market the company’s products to customers within its three anticipated revenue streams, supply chain constraints, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. oilprice.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.